Loading ...
Sorry, an error occurred while loading the content.

ScienceDaily Magazine -- Antiviral Drug Works By Causing Genetic Meltdown.htm

Expand Messages
  • Alley/Pat
    ScienceDaily Magazine -- Antiviral Drug Works By Causing Genetic Meltdown http://www.sciencedaily.com/releases/2000/12/001208073913.htm Search ScienceDaily:
    Message 1 of 1 , Mar 2, 2001
      ScienceDaily Magazine -- Antiviral Drug Works By Causing "Genetic Meltdown"http://www.sciencedaily.com/releases/2000/12/001208073913.htm
      Search ScienceDaily:
      Find in News Talk Sites Images
      For advanced search options, click here.
      Subscribe for free email updates.

      Ad- Free
      Click here
      to sign up,
      or log in.

      Home page
      About this site
      Awards, reviews
      Privacy policy

      News Pages
      News by topic
      Find stories

      Talk of the day
      Find postings

      Web Links
      Site of the day
      Site categories
      Find sites

      Image Gallery
      Pic of the day
      Image categories
      Find images

      Science Shop
      Browse books

      Register free
      Post release
      Edit profile
      Review hits

      Media kit
      Traffic stats
      Contact us

      this story Printer-friendly
      version Previous
      story Next

      Source: Howard Hughes Medical Institute (http://www.hhmi.org)

      Date: Posted 12/11/2000

      Antiviral Drug Works By Causing "Genetic Meltdown"

      December 7, 2000 - The antiviral drug ribavirin works by creating such extreme mutation rates in viruses that it drives them into "genetic meltdown," according to researchers. Uncovering the mechanism by which ribavirin disables viruses offers researchers information that can be used to design more effective antiviral drugs.
      Ribavirin's mutagenic mechanism was reported in the December 2000 issue of Nature Medicine by a research team that included lead author Shane Crotty, who is a Howard Hughes Medical Institute predoctoral fellow at the University of California, San Francisco (UCSF), Craig Cameron at Pennsylvania State University and scientists from Schering-Plough Research Institute.

      "Ribavirin is one of the few drugs that shows activity against a variety of RNA viruses," said Crotty. These viruses use RNA rather than DNA as their genetic material. Ribavirin is used to treat severe cases of respiratory syncytial viruses in children, lassa fever and hepatitis C infections, where it is used in combination with interferon-alpha.

      "Unfortunately, only about thirty to forty percent of hepatitis C patients respond to the treatment," said Crotty. "Once people are chronically infected, they don't appear to get rid of the virus and there is a high incidence of liver failure in these patients. Nevertheless, ribavirin plus interferon-alpha is the closest we've gotten to a cure right now," he said.

      Thus, said Crotty, there is a great deal of interest among pharmaceutical companies in understanding ribavirin's mechanism of action. Researchers have suggested several theories about how ribavirin works, including speculation that ribavirin blocks viral protein synthesis or that it halts the transcription of RNA needed for viral replication.

      To determine whether ribavirin does, indeed, interfere with RNA transcription, Cameron and his colleagues used a sensitive analytical assay to see whether ribavirin is incorporated into viral RNA. Those experiments revealed that a form of the drug called ribavirin triphosphate (RTP) is incorporated into viral RNA. RTP resembles the nucleotide building blocks that normally make up RNA.

      "This finding was reasonable to expect because other antiviral drugs that resemble nucleotides are also incorporated into the viral genetic material, acting as chain terminators to block further RNA elongation," said Crotty. "However, what was confusing was that Cameron's experiments also showed that ribavirin was not a chain terminator because RNA translation continued," he said.

      To understand how ribavirin affects viruses in vivo, Crotty, working in the laboratory of Raul Andino at UCSF, tested the drug's effect on live poliovirus using an assay he had developed to determine the level of mutation in poliovirus. Crotty's assay measured how frequently poliovirus in culture mutates to develop resistance to the molecule guanidine, both in the absence and in the presence of ribavirin. Crotty's measurements revealed that ribavirin increased the mutation rate of the poliovirus cultures by a large amount.

      "Normally, a high rate of mutation is a survival trait used by viruses such as HIV, influenza and poliovirus to escape the immune system or to develop resistance to antiviral drugs," explained Crotty. "Importantly, data from other researchers studying poliovirus have indicated that the virus is mutating as much as it possibly can, and if it mutates any more, it starts dying. Its genetic information is degraded so much that it doesn't make sense.

      "My experiments convinced me that ribavirin is pushing poliovirus into what's called an 'error catastrophe'-in other words, a genetic meltdown," said Crotty.

      Evidence that ribavirin pushes viruses to mutate suggests that the apparent failure of clinical trials of ribavirin used alone against hepatitis C virus might not have been real failures, said Crotty. "Nobody knows how to grow hepatitis C in culture, so there is no assay to determine how much viable virus is left after treatment with ribavirin," said Crotty. "So, to indicate clinical effectiveness, those studies measured the blood levels of viral RNA. My data suggest that while viral RNA is present in the blood, it might be mutated to the point where it is useless."

      Of broader importance, said Crotty, is that this discovery offers hope that pharmaceutical companies may be able to develop improved versions of ribavirin or completely new nucleotide mimics that can also be incorporated into the viral RNA to induce lethal genetic meltdown in RNA viruses.

      Editor's Note: The original news release can be found at http://www.hhmi.org/news/crotty.html


      Note: This story has been adapted from a news release issued by Howard Hughes Medical Institute for journalists and other members of the public. If you wish to quote from any part of this story, please credit Howard Hughes Medical Institute as the original source. You may also wish to include the following link in any citation:



      stories Related
      discussions Related
      web sites Related

      Copyright © 1995-2001 ScienceDaily Magazine | Email: editor@...
      Best viewed with Internet Explorer or Netscape Navigator (version 3.0 or higher)

      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.